Literature DB >> 17706174

Functionalized N(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents.

Saeed Rajabalian1, Alireza Foroumadi, Abbas Shafiee, Saeed Emami.   

Abstract

PURPOSE: The prokaryotic type II topoisomerases (DNA gyrase and topoisomerase IV) and the eukaryotic type II topoisomerases represent the cellular targets for quinolone antibacterial agents and a wide variety of anticancer drugs, respectively. In view of the mechanistic similarities and sequence homologies exhibited by the two enzymes, tentative efforts to selectively shift from an antibacterial to an antitumoral activity was made by synthesizing a series of functionalized N-(2-oxyiminoethyl)piperazinyl quinolones, in which the C-7 piperazine ring of antibacterial quinolones, ciprofloxacin and norfloxacin, is attached by a certain N-[2-(furan-2-yl)-2-oxyiminoethyl] and N-[2-(thiophen-2-yl)-2-oxyiminoethyl] moieties. Thus, as part of a continuing search for potential anticancer drug candidates in the N-substituted piperazinyl quinolones series, the cytotoxicity evaluation of functionalized N-(2-oxyiminoethyl) piperazinyl quinolones was our interest.
METHODS: The growth inhibitory activities of synthesized N-[2-(furan-2-yl)-2-oxyiminoethyl] and N-[2-(thiophen-2-yl)-2-oxyiminoethyl] piperazinyl quinolones were determined against seven cancer cell lines using an in vitro cell culture system (MTT assay).
RESULTS: Preliminary screening showed that some of N-(2-oxyiminoethyl) piperazinyl quinolone analogs containing O-benzyl group displayed in vitro cytotoxic activity comparable or higher than reference drug etoposide.
CONCLUSIONS: These studies demonstrate that introduction of O-benzylmoiety on oxime group of N-(2-oxyimino) piperazinyl quinolone series changes the biological profile of piperazinyl quinolones from antibacterial to cytotoxic activity. As can be deduced from these data, O-benzyl functionalized N-(2-oxyiminoethyl) piperazinyl quinolones have excellent potential as a new class of cytotoxic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706174

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  6 in total

1.  Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells.

Authors:  Zhen-yu Shi; Yong-qiang Li; Yu-hua Kang; Guo-qiang Hu; Chao-shen Huang-fu; Jin-Bo Deng; Bin Liu
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

2.  Potent Antimalarial 2-Pyrazolyl Quinolone bc 1 (Qi) Inhibitors with Improved Drug-like Properties.

Authors:  W David Hong; Suet C Leung; Kangsa Amporndanai; Jill Davies; Richard S Priestley; Gemma L Nixon; Neil G Berry; S Samar Hasnain; Svetlana Antonyuk; Stephen A Ward; Giancarlo A Biagini; Paul M O'Neill
Journal:  ACS Med Chem Lett       Date:  2018-10-19       Impact factor: 4.345

3.  Characterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacin.

Authors:  Béatrice Marquez; Geneviève Ameye; Coralie M Vallet; Paul M Tulkens; Hélène A Poirel; Françoise Van Bambeke
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

4.  Novel N-2-(Furyl)-2-(chlorobenzyloxyimino) Ethyl Piperazinyl Quinolones: Synthesis, Cytotoxic Evaluation and Structure-Activity Relationship.

Authors:  Negar Mohammadhosseini; Mahboobeh Pordeli; Maliheh Safavi; Loghman Firoozpour; Fatame Amin; Sussan Kabudanian Ardestani; Najmeh Edraki; Abbas Shafiee; Alireza Foroumadi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

5.  Trimethoxy-benzaldehyde levofloxacin hydrazone inducing the growth arrest and apoptosis of human hepatocarcinoma cells.

Authors:  Jin-Ping Sun; Zhen-Yu Shi; Shi-Meng Liu; Yu-Hua Kang; Guo-Qiang Hu; Chao-Shen Huangfu; Jin-Bo Deng; Bin Liu
Journal:  Cancer Cell Int       Date:  2013-07-02       Impact factor: 5.722

Review 6.  Recent progress in the development of anti-malarial quinolones.

Authors:  Richard M Beteck; Frans J Smit; Richard K Haynes; David D N'Da
Journal:  Malar J       Date:  2014-08-30       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.